Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05697510
Title Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM (SILTUXILAM)
Acronym SILTUXILAM
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Nantes University Hospital
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Additional content available in CKB BOOST